BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24173088)

  • 21. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
    Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
    J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. When Hodgkin comes to a head: Hodgkin central nervous system involvement.
    Hathaway AR; Amadon JP; Keith BA
    Am J Med Sci; 2015 Jun; 349(6):552-3. PubMed ID: 25723883
    [No Abstract]   [Full Text] [Related]  

  • 23. Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission.
    Pingali SR; Jewell SW; Havlat L; Bast MA; Thompson JR; Eastwood DC; Bartlett NL; Armitage JO; Wagner-Johnston ND; Vose JM; Fenske TS
    Cancer; 2014 Jul; 120(14):2122-9. PubMed ID: 24711253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hodgkin Lymphoma Presentation With Extensive Chest Wall Muscle Involvement in an Adult.
    Gorospe L; Chinea-Rodríguez A; García-Cosío-Piqueras M; Calbacho-Robles M; Almeida-Aróstegui NA
    Ann Thorac Surg; 2018 Jul; 106(1):e37. PubMed ID: 29452117
    [No Abstract]   [Full Text] [Related]  

  • 25. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
    Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
    J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.
    Gandikota N; Hartridge-Lambert S; Migliacci JC; Yahalom J; Portlock CS; Schöder H
    Cancer; 2015 Jun; 121(12):1985-92. PubMed ID: 25739719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
    Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
    Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
    [No Abstract]   [Full Text] [Related]  

  • 28. ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma.
    Ferrario A; Radaelli F; Goldaniga M; F FG; Olivero B; Rossi F; Baldini L
    Leuk Res; 2010 Oct; 34(10):e280-1. PubMed ID: 20605208
    [No Abstract]   [Full Text] [Related]  

  • 29. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
    Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.
    Kasamon YL; Jacene HA; Gocke CD; Swinnen LJ; Gladstone DE; Perkins B; Link BK; Popplewell LL; Habermann TM; Herman JM; Matsui WH; Jones RJ; Ambinder RF
    Blood; 2012 May; 119(18):4129-32. PubMed ID: 22343727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
    Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C
    J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired Glanzmann thrombasthenia associated with Hodgkin lymphoma: rapid reversal of functional platelet defect with ABVD (adriamycin/bleomycin/vinblastine/dacarbazine) chemotherapy.
    Raman V; Quillen K; Sloan JM
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e51-4. PubMed ID: 24342105
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of Hodgkin lymphoma: a 50-year perspective.
    Canellos GP; Rosenberg SA; Friedberg JW; Lister TA; Devita VT
    J Clin Oncol; 2014 Jan; 32(3):163-8. PubMed ID: 24441526
    [No Abstract]   [Full Text] [Related]  

  • 34. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
    J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Doxorubicin, bleomycin, vinblastine, and dacarbazine alone in treatment of favorable, limited-stage Hodgkin's lymphoma: do we really have robust data?
    Basaran G; Agaoglu F; Basaran M
    J Clin Oncol; 2010 Sep; 28(27):e485-6; author reply e487. PubMed ID: 20606082
    [No Abstract]   [Full Text] [Related]  

  • 37. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.
    Connors JM; Ansell SM; Fanale M; Park SI; Younes A
    Blood; 2017 Sep; 130(11):1375-1377. PubMed ID: 28733323
    [No Abstract]   [Full Text] [Related]  

  • 38. Renal Hodgkin's disease.
    Pilatrino C; Cataldi A; Guerrasio A; Saglio G
    Br J Haematol; 2002 Mar; 116(4):732. PubMed ID: 11886375
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
    Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hodgkin lymphoma among patients infected with HIV in post-HAART era.
    Tanaka PY; Pessoa VP; Pracchia LF; Buccheri V; Chamone DA; Calore EE
    Clin Lymphoma Myeloma; 2007 Mar; 7(5):364-8. PubMed ID: 17562247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.